Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Susan Weiner, MS, is a diabetes care and education specialist and the founder and owner of Susan Weiner Nutrition, PLLC.

US 2025-2030 Dietary Guidelines: Addressing Alcohol Intake Recommendations

The US Department of Health and Human Services and the US Department of Agriculture released the 2025-2030 Dietary Guidelines for Americans on January 7, 2026. Along with establishing the first-ever limit on processed foods, firmly encouraging a focus on whole foods, and recommending a higher proportion of protein, the guidelines come with several uncertainties and limitations.

Prominent among these uncertainties is a significantly broader suggestion of how people should manage their alcohol intake. Rather than explicitly stating a recommended number of drinks, the guidelines now advise patients to limit their alcohol intake. To address and attempt to explain this vague suggestion, Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, met with Susan Weiner, MS, a nationally recognized dietitian and diabetes care and education specialist.

Check out the full episode on the 2025-2030 Dietary Guidelines for Americans 

Weiner opens by raising substantive concerns about revisions to alcohol-related recommendations in the newly released US dietary guidelines, emphasizing the clinical and policy implications of shifting from quantitative to more ambiguous language. She notes that previous guidelines clearly defined alcohol limits—less than two drinks per day for men and one drink per day for women—while also specifying standard drink sizes and citing evidence linking alcohol consumption to adverse outcomes such as cancer, liver disease, metabolic dysfunction, and other chronic conditions. In contrast, the updated guidance broadly advises individuals to “drink less,” without numerical thresholds, detailed definitions, or accompanying references to alcohol-related harms. Weiner argues that this lack of specificity reduces the guidance’s practical value for clinicians and increases the risk of misinterpretation by patients, who may rationalize unsafe drinking behaviors under vague recommendations.

The discussion highlights how this ambiguity is particularly concerning in populations with diabetes or alcohol-induced dysglycemia, where alcohol can acutely and chronically disrupt glucose regulation, exacerbate liver disease, and affect multiple organ systems. Bellini reflects on the importance of having firm, evidence-based language that clinicians can reference directly in counseling and documentation, noting that tighter guidance previously served as a useful clinical tool. Bellini expresses worry that the revised wording may be perceived as a loosening of standards, potentially undermining public health messaging at a time when alcohol consumption increased during and after the COVID-19 pandemic.

Beyond individual patient care, the conversation emphasizes that dietary guidelines function as policy instruments. Weiner notes that these recommendations shape nutrition education curricula taught to children, influence school lunch programs, and may affect federal food and nutrition programs such as WIC, SNAP, and even military food services. From this vantage point, changes to alcohol guidance could have broad societal consequences, reinforcing the need for clarity and scientific rigor.

The segment also explores how professional organizations interpret and adopt federal dietary guidelines. Isaacs observes that groups such as the American Heart Association appear to be maintaining more conservative, established recommendations (such as the plate method, emphasis on lean meats, and limiting saturated fats) despite broader inclusions in the new guidelines, including butter and beef tallow. Weiner anticipates that organizations focused on cardiovascular disease, cancer, and metabolic health will publicly scrutinize and potentially challenge the revised alcohol language, given its established links to disease, mental health outcomes, and excess caloric intake. The discussion concludes with the expectation that further debate and guidance from professional societies will emerge, underscoring that alcohol cannot be excluded from clear, evidence-based dietary recommendations.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Weiner reports no relevant disclosures.

Mozaffarian D. The 2025-2030 Dietary Guidelines for Americans. JAMA. Published online January 14, 2026. 

Videos

This segment of Diabetes Dialogue spotlights the new guidelines’ broad suggestion regarding alcohol, as well as how organizations may interpret it.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

New data suggest care improvements can be made for patients with skin cancer who have frail skin through collaboration with geriatricians, the use of a geriatric assessment, and an onco-geriatric multidisciplinary team (OMDT).

These results were the conclusion of a recently-published letter to the editor in the Journal of the European Academy of Dermatology and Venereology (JEADV). It was authored by such investigators as Esther Groll, from the University Medical Center Groningen Department of Dermatology.

Groll et al noted the prognostic value of evaluating frailty in a patient’s skin, though the condition is rarely addressed within patient guidelines. Such guidelines, they highlighted, most often prioritize the characteristics of skin cancer tumors instead.

“The University Medical Center Groningen recently introduced a nurse-led frailty assessment to improve care for this population,” the investigators wrote.

 “We investigated how this screening affected treatment choices and time to treatment.”

Although the Comprehensive Geriatric Assessment (CGA) is considered the reference standard for assessing older oncology patients, Groll and colleagues pointed to the substantial time and resources needed for the CGA’s use. Consequently, this nurse-led frailty screening program was evaluated in its aim to make improvements to older patient care, specifically among those living with skin cancer. They used a retrospective case–control study design, assessing the program’s effects on treatment decision-making and treatment timelines.

There were 290 patients aged 65 years or older involved in this study, all of whom were described as having head and neck skin malignancies.In specific, the study subjects had either cutaneous squamous cell carcinoma, lentigo maligna, or basal cell carcinoma. 145 of the study subjects were screened for frailty in the timeframe between 2022 - 2023. The study’s outcomes were compared with those of a matched historical control cohort of 145 individuals treated between 2018 - 2019 at the same institution.

Matching was done by Groll and coauthors based on sex, diagnosis, and age. The identification of the study’s control cohort was done via the Netherlands Cancer Registry. Individuals included in the control arm of the analysis were not provided with this frailty screening as part of their course of care. The frailty evaluation was conducted through the use of a shortened geriatric evaluation covering 4 domains:

If a participant was shown to have impairments in 2 or more domains, they would be described as frail. Reviews of treatment plans and decisions related to referrals for CGA by a geriatrician were done by an OMDT. This OMDT was made up of a specialized nurse, a dermatologist, a geriatrician, and a radiotherapist. Assessments in this analysis looked at estimated life expectancy, frailty status, and preferences among patients.

114 of the screened patients were labeled by Groll et al as frail (78.6%). The investigative team pointed to functional and psychocognitive impairments as the most commonly observed contributors to frailty. They found 53.8% were reviewed by the OMDT. Changes to treatment were made in 20.7% of these cases. In 1 notable finding, 83.3% of the treatment changes were described as having involved a shift toward less invasive therapeutic choices.

A strong association was identified between the use the OMDT and treatment modifications (OR 5.85, 95% CI 2.09–16.35, 

 < .001). Additionally, a strong link was identified with the selection of less invasive treatments (OR 0.16, 95% CI 0.05–0.52, 

 = .002). Overall, 17.2% of the subjects screened by Groll and colleagues were referred for a CGA. Among 44% of these individuals, Mohs micrographic surgery was replaced with a less invasive alternative.

In contrast, only 4.8% of those inclucded in the historical cohort were provided with treatment diverging from guideline-based recommendations. This was described by the team as a significant difference versus those involved in the screened cohort (

Those who underwent this frailty screening attended more hospital visits on average (median 6 versus 4, 

 < .001), reported longer median interval to initiation of their treatment compared with those in the control arm (62 versus 41.5 days, 

 < .001), and presented with larger median tumor diameters (14 versus 9 mm, 

 < .001). Overall, frailty screening identified a high prevalence of patient frailty and, via the integration of geriatric expertise and patient-centered considerations, supported the implementation of treatment actions considered less aggressive.

“This aligns with prior research that stresses the importance of shared decision-making and incorporation of comorbidities, functional status and life expectancy to guide care and reduce treatment burden,” Groll and coauthors wrote.

Groll E, Hetényi Z, Rácz E. Personalized care for older skin cancer patients: Impact of frailty screening on treatment decisions. J Eur Acad Dermatol Venereol. 2026 Jan 16. 

van Winden MEC, Garcovich S, Lubeek SFK. Frailty screening in dermato-oncology practice: a modified Delphi study and a systematic review of the literature. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):95-104. doi: 10.1111/jdv.16607. Epub 2020 Jul 1. PMID: 32403174; PMCID: PMC7818261.

Articles

Recent findings indicate that integrating geriatric assessments and multidisciplinary teams can enhance care for older skin cancer patients with frail skin. A study involving 290 patients aged 65 and older with head and neck skin malignancies demonstrated that nurse-led frailty screenings influenced treatment decisions, often leading to less invasive options. The study highlighted the importance of considering frailty, functional status, and life expectancy in treatment planning. The use of an onco-geriatric multidisciplinary team was associated with significant treatment modifications and improved patient-centered care.

These data suggest improvement of care for patients with skin cancer and frail skin through geriatrician use, along with a nurse-led geriatric assessment, may be beneficial.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Personalized Care Improvements Identified for Older Patients with Skin Cancer

Michael E. Thase, MD, of the University of Pennsylvania

Adjunctive Lumateperone Improves Remission Rates in MDD, With Michael E. Thase, MD

Achieving sustained remission remains a central challenge in the management of 

, particularly for patients who fail to respond adequately to antidepressant therapy (ADT) alone. New pooled analyses evaluating lumateperone 42 mg as an adjunct to ADT provide encouraging evidence for both short-term efficacy and long-term durability, as discussed by Michael E. Thase, MD, of the University of Pennsylvania, in a recent interview.

“[Patients who do not respond easily to antidepressants are not only at grave risk for continuing to suffer and continuing to do poorly at work and in their social roles, but they are also more likely to then become chronically depressed,” Thase told 

. “It's not just enough to help them feel better over 6 weeks or 8 weeks or in the short run, but it's really important for the benefits to be sustained and for the treatment benefit not to dissipate.”

He provided the example of weight gain, which can appear relatively small in 6 weeks but large over 6 months.

“I'm glad to say that in the long term…the benefits were sustained,” Thase continued. “People did, on average, continue to improve if they had not had a full remission with the first 6 weeks of treatment [and] that that could happen with continued treatment. There was very little cost for the continued treatment in terms of the risk of weight gain or the development of new side effects.”

In pooled short-term studies, presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting in the Bahamas from January 12 – 15, 2026, lumateperone 42 mg plus ADT demonstrated significantly greater Montgomery–Åsberg Depression Rating Scale (MADRS) total score remission rates compared with placebo plus ADT by day 43 (25.5% vs 13.6%; 

 <.0001). Complete remission was achieved by 10.6% of patients receiving lumateperone versus 5.6% of those receiving placebo, highlighting the clinical relevance of early symptom resolution in patients with an inadequate response to ADT (

 <.01). In a separate long-term trial, complete remission was achieved by 44.1% of patients.

During the open-label phase, 65.4% of patients achieved remission. In each subgroup analysis, over 55% of patients receiving lumateperone plus ADT achieved remission at the end of the trial. Remission rates were similar despite age, ADT treatment, or baseline disease severity.

Tolerability further distinguishes lumateperone from other adjunctive options. Across studies, treatment was associated with minimal weight gain, low discontinuation rates, and a favorable neurologic safety profile, with little evidence of akathisia or extrapyramidal symptoms—concerns that often limit long-term use of other adjunctive agents.

“I want clinicians to know that we not only have a new therapy that's been approved for this purpose now, lumateperone has been approved for several years for the treatment of schizophrenia, but now it's approved for the adjunctive treatment of major depressive disorder and that it is effective… [and] effective relatively quickly,” Thase said. “There's only a single therapeutic dose, 42 milligrams, so it's easy to get the dose right. It's really well tolerated; very few patients drop out there. There's little, if [any], weight gain associated with the treatment. Patients are unlikely to have uncomfortable, neurologic side effects such as restlessness or stiffness…We're delighted that the results turned out so well.”

Relevant disclosures for Thase include Otsuka Pharmaceutical, Janssen Scientific Affairs, E.R. Squibb & Sons, Eli Lilly and Company, H. Lundbeck A S, Boehringer Ingelheim International GmbH, and ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.).

Bhagwagar Z, Durgam S, Earley W, et al. Remission with lumateperone 42 mg adjunctive to antidepressant therapy in patients with Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials. Presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting in Bahamas from January 12 – 15, 2026

Lumateperone 42 mg plus antidepressants boosts remission rates and sustains symptom improvement in MDD patients, says Michael E. Thase, MD.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Tyrosine kinase 2 (TYK2) inhibitor and interleukin (IL)-23 pathway biologic medication use is linked with comparable alleviation of 

 lesions and comorbid depressive symptoms, new data suggest.

These findings were drawn from a recently-published analysis authored by such investigators as Lanmei Lin, MD, from Huashan Hospital of Fudan University in Shanghai. In their study background, Lin and coauthors highlighted TYK2 as a key regulatory molecule and novel therapeutic target for psoriasis, given its role in IL-23/Th17 signal transduction.

“Clinically, TYK2 inhibitors significantly alleviated both the cutaneous manifestations and depressive symptoms in our cohort of psoriasis patients,” the investigative team wrote.

 “These findings provide clinical evidence supporting further investigation into the mechanisms by which TYK2 inhibitors ameliorate comorbid depression in psoriasis.”

Lin and colleagues conducted their study using 2 distinct phases, with the first being a cross-sectional evaluation of patients with psoriasis involving the collection of Hospital Anxiety and Depression Scale (HADS) questionnaire data. These data were gathered from 298 individuals living with psoriasis. In the second phase, the study used a retrospective longitudinal evaluation of 107 individuals evaluated by the investigators prior to and after receiving 3 months of TYK2 inhibitor therapy.

A clinically confirmed diagnosis of psoriasis was required by the investigative team for inclusion. Patients would not be involved if their disease was treatment-induced or if they had any comorbid systemic conditions linked with substantial immune compromise. Such conditions included infectious, hematologic, hepatic, neurologic, renal, or pulmonary disorders. The team would provide HADS questionnaires to participants over the course of their routine outpatient clinic interactions.

Within this cross-sectional cohort of 298 subjects, stratification into 3 treatment categories took place:

Within the non-JAK pool, participants were given IL-23 biologics, IL-17 biologics, or other medications. This classification was chosen to minimize overlap in JAK pathway inhibition across cohorts. Any associations between treatment arms and HADS outcomes were assessed through the use of generalized linear models (GENMOD). The analyses accounted for several potential confounders, including sex, Psoriasis Area and Severity Index (PASI), age, involvement of body surface area (BSA), utilization of systemic or biologic drugs within the preceding 12 months, duration of psoriasis, and history of phototherapy use.

When depressive symptoms were assessed through the use of HADS-D scores, individuals given treatment with TYK2 inhibitors were shown to have significantly lower scores as opposed to participants in the non-JAK arm, with a β coefficient of 1.23 (95% CI, 0.37 - 2.10).

 In contrast, Lin et al found no statistically significant distinctions between those included in the TYK2 inhibitor cohort and those given IL-23 biologics (β = 0.67; 95% CI, −0.76 to 2.10) or given JAK inhibitors (β = 0.84; 95% CI, −1.54 to 3.21).

In their exploratory molecular analyses, the investigative team highlighted additional mechanistic insights. In particular, they noted transcriptomic profiling of peripheral blood samples suggested a marked downregulation of genes involved in long-term depression–related pathways, IL-6 receptor signaling, and Th17 cell differentiation, alongside the upregulation of pathways connected to neuronal activity.

In complementary analyses, Lin et al’s data suggested the presence of reduced levels of kynurenic acid, a metabolite known to be linked with pro-inflammatory signaling as well as depressive symptoms. They also suggested the presence of increased concentrations of 1H-indole-3-propanoic acid, known to have anti-inflammatory and neuroprotective properties. These omics-based conclusions were interpreted by the investigative team cautiously, as false discovery rate (FDR) correction was applied to account for multiple testing.

In all, Lin and coauthors’ findings point to the value of a proposed mechanism whereby TYK2 inhibition may work to interrupt a sustained cycle connecting peripheral inflammation and central depressive processes. This, they note, could potentially be done via the modulation of the IL-23/Th17 pathway and the IL-6–tryptophan metabolic axis in such patients. The team then noted the significance of these conclusions.

“These findings offer new therapeutic possibilities for psoriasis—a prototypical psychodermatological condition—and underscore the importance of multidimensional targeting along the neuro–immune–cutaneous axis as a pivotal strategy for managing psoriasis–depression comorbidity,” Lin et al wrote.

Lin L, Dong C, Du J, et al. TYK2 and IL-23 Pathway Therapies in Psoriasis: Associations With IL-6, Tryptophan Metabolism, and Depressive Symptoms. Int J Dermatol. 2026 Jan 12. 

Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006. PMID: 32427307.

Recent research indicates that TYK2 inhibitors and IL-23 pathway biologics provide similar relief for psoriasis lesions and associated depressive symptoms. The study involved a cross-sectional and longitudinal evaluation of psoriasis patients, revealing that TYK2 inhibitors significantly reduced depressive symptoms compared to non-JAK treatments. Molecular analyses suggested TYK2 inhibitors may disrupt the link between peripheral inflammation and central depression by modulating the IL-23/Th17 pathway and IL-6–tryptophan metabolic axis. These findings highlight the potential of targeting the neuro–immune–cutaneous axis in managing psoriasis and depression comorbidity.

This analysis suggests TYK2 (tyrosine kinase 2) inhibitors may have a dual therapeutic potential to address both skin symptoms of psoriasis and comorbid depressive symptoms.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

TYK2, IL-23 Pathway Treatments Assessed in Psoriasis for Lesions, Depressive Symptoms

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Recent findings revealed differences in relapse rates and kidney function decline between adolescents and young adults with glomerular disease and older adult patients. 

However, these disparities might stem from a lack of understanding regarding age-specific care in these patient populations.

“Adolescents and young adults are often navigating major life transitions: finishing high school, starting college or a job, moving away from home, and developing independence,” said Andrew Vissing, MD, attending physician and assistant professor at Northwestern University Feinberg School of Medicine, in an interview with 

. “For patients with chronic diseases like glomerular disease, these transitions can make disease management more difficult. Prior studies in kidney transplantation have shown that this age group experiences worse outcomes than both younger children and older adults, which motivated us to explore whether similar patterns exist in glomerular disease.”

Data from the Cure Glomerulonephropathy (CureGN) consortium, a network of investigators studying glomerular diseases in pediatric and adult populations, underscored the need for age-differentiated care and outcome assessment in this patient population.

Glomerular disease affects millions worldwide, with >17 million individuals developing 

 secondary to glomerulonephritis in 2019. Since 1990, incident cases have increased by 77% and prevalent cases by 81%. In the United States, glomerulonephritis accounts for approximately 10–15% of all end-stage kidney disease (ESKD) and represents the third leading cause.

The most common forms of glomerular disease include

focal segmental glomerulosclerosis (FSGS)

, all of which are associated with substantial morbidity and impaired quality of life.

According to CureGN investigators, glomerular disease outcomes are often defined using arbitrary age cutoffs, typically separating pediatric and adult populations at 18 years. The current analysis aimed to address this gap by defining adolescents and young adults as a distinct group when evaluating disease trajectories.

In minimal change disease (MCD), investigators observed several differences across age groups. Adults experienced fewer relapses compared with young adults (incidence rate ratio [IRR], 0.61; 95% Confidence Interval [CI], 0.41-0.91;

 = .01), whereas relapse rates did not differ between pediatric patients and young adults (IRR, 1.23; 95% CI, 0.85–1.79; 

 = .28). Pediatric patients with MCD also achieved first observed remission more rapidly than young adults (hazard ratio [HR], 2.18; 95% CI, 1.03-4.63; 

Among patients with IgAN, adults experienced fewer relapses than young adults (IRR, 0.55; 95% CI, 0.33-0.94; 

 = .03). Adults with IgAN were also slower to achieve first observed remission compared with young adults (HR, 0.58; 95% CI, 0.37=0.91; 

In FSGS, kidney function declined more rapidly among young adults, with an estimated decline of 1.7 mL/min/1.73 m² per year compared with 0.3 mL/min/1.73 m² per year in pediatric patients (

“One of the main takeaways is not any single outcome, but rather the consistent finding that adolescents and young adults experience different disease trajectories,” Vissing said. “This suggests that clinicians and researchers should not lump these patients into pediatric or adult categories based on an arbitrary age cutoff, but instead consider them as a distinct population.”

Vissing A, Fishbein J, Smith AR, et al. Is Age Just a Number? 

. Published online December 23, 2025. doi:

Balakrishnan S, Thongprayoon C, Craici IM, Cheungpasitporn W, Miao J. Global and national public awareness and interest in glomerular diseases from 2004 to 2024. 

https://doi.org/10.3389/fneph.2025.1519481

New CureGN findings and an interview with Andrew Vissing, MD, highlight distinct glomerular disease outcomes in adolescents and young adults compared with pediatric and adult patients


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Unmet Needs of Glomerular Disease in Young Adults, Adolescents With Andrew Vissing, MD

In ‘Novel Approaches in Hypoparathyroidism Management,’ our experts delve into novel treatment options for patients who are inadequately controlled on conventional therapy and the mechanism of action of palopegteriparatide.

Video Series

Novel Approaches in Hypoparathyroidism Management

In this episode, ‘Challenges of Conventional Therapy in Hypoparathyroidism,’ the expert endocrinologists explore conventional therapy for chronic hypoparathyroidism, symptom control, and the risk of complications. 


Challenges of Conventional Therapy in Hypoparathyroidism

In ‘Acute and Long-Term Complications of Hypoparathyroidism,’ our panel delves into the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

Quality of Life Impact in Hypoparathyroidism

In ‘Acute and Long-Term Complications of Hypoparathyroidism,’ our panel delves into the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

Led by the moderator, Dr. Kohlmeier, the expert panel, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examines the following critical questions: 

1.	How is hypoparathyroidism diagnosed? 
2.	What are the key challenges in both diagnosing and monitoring patients with hypoparathyroidism? 

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘Acute and Long-Term Complications of Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

Acute and Long-Term Complications of Hypoparathyroidism

The panel concludes by discussing the future of ATTR-CM care. They highlight continued progress in disease-modifying therapies, with growing interest in determining how best to sequence or potentially combine treatments as evidence evolves. The group notes that as patients are diagnosed earlier, the goals of therapy may increasingly shift from slowing decline to preserving long-term function and quality of life.
They emphasize the importance of expanding awareness and education across specialties so that more patients are recognized before advanced cardiac dysfunction develops. Improving access to therapy remains an essential area of focus, as cost and insurance barriers continue to influence treatment decisions. The panel also anticipates advances in monitoring disease progression, including the use of biomarkers and imaging to better assess response over time.
Ultimately, the experts express optimism that ongoing research, broader recognition, and more refined care pathways will continue to improve outcomes for individuals living with ATTR-CM.


Future Directions in ATTR-CM

 In this episode, ‘Hypoparathyroidism Diagnosis and Challenges,’ the panelists explore how hypoparathyroidism is diagnosed as well as key diagnostic and monitoring challenges that clinicians face.

Led by the moderator, Dr. Kohlmeier, the expert panel, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examines the following critical questions: 

1.	How is hypoparathyroidism diagnosed? 
2.	What are the key challenges in both diagnosing and monitoring patients with hypoparathyroidism? 

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘Acute and Long-Term Complications of Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

Hypoparathyroidism Diagnosis and Challenges

See how shared EHRs support collaborative care and review newer steroid-sparing topical therapies for pediatric atopic dermatitis and psoriasis.

EHR Collaboration and New Steroid-Sparing Topicals in Pediatric Dermatoses

Welcome back to another HCPLive Peer Exchange series. In this opening episode, panelists highlight the underlying causes of hypoparathyroidism and the impact of the loss of parathyroid hormone function by examining the following critical questions:

1.	What is chronic hypoparathyroidism, and how is it defined? 
2.	How does the loss of parathyroid hormone (PTH) function disrupt calcium and phosphate homeostasis in hypoparathyroidism? 
3.	What are the causes of chronic hypoparathyroidism, and is there any way to predict or prevent it? When might genetic testing be appropriate?

In the next episode, panelists will continue their discussion on hypoparathyroidism and highlight how it is diagnosed and the key challenges in the diagnosis and monitoring of patients with hypoparathyroidism.

Defining Hypoparathyroidism

The panel discusses the importance of shared decision-making in the care of patients with ATTR-CM. They emphasize that treatment conversations are often ongoing rather than single moments, as patients and families may need time to understand the diagnosis, the goals of therapy, and what to expect over time. The clinicians highlight the role of clear, honest communication, particularly when addressing uncertainty around disease progression or response to therapy.
The group describes how patient preferences can influence treatment selection, including the choice between oral therapies and periodic injections, the desire to minimize medication burden, and the importance of maintaining independence and daily routines. They also note that caregivers are crucial partners in supporting adherence, appointment planning, and monitoring changes in function or symptoms. Ultimately, the panel agrees that successful care depends on making decisions with patients, ensuring they understand their options, and aligning treatment plans with their values, goals, and quality-of-life priorities.


Patient Engagement and Shared Decision-Making in ATTR-CM

Sidhartha Sinha, MD, is an assistant professor of gastroenterology and hepatology at Stanford University.

Sinha describes data supporting the safety and utility of a fasting-mimicking diet in Crohn’s disease and explores what may be next in this line of research.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Latest News

US 2025-2030 Dietary Guidelines: Addressing Alcohol Intake Recommendations

Personalized Care Improvements Identified for Older Patients with Skin Cancer

Adjunctive Lumateperone Improves Remission Rates in MDD, With Michael E. Thase, MD

TYK2, IL-23 Pathway Treatments Assessed in Psoriasis for Lesions, Depressive Symptoms

Unmet Needs of Glomerular Disease in Young Adults, Adolescents With Andrew Vissing, MD